Johnson & Johnson stock slips 1.17% to EUR 237.88 premarket
Published on 11/04/2026 at 08:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Johnson & Johnson focuses on healthcare innovation spanning disease prevention, treatment and cures.
- The company says more than 75 percent of sales come from products holding a number-one or number-two global market-share position.
- Investor attention remains on the company’s pharmaceutical and medical-device operations.
Johnson & Johnson stock traded at EUR 237.88 on Lang & Schwarz at 07:59 CET on Wednesday, November 4, 2026, 1.17 percent below the Xetra close of Tuesday, November 3, 2026 at EUR 240.70.
The company operates across healthcare, with activities spanning pharmaceutical products and medical devices. On its investor-relations site, Johnson & Johnson describes its focus as healthcare innovation aimed at preventing, treating and curing complex diseases.
Johnson & Johnson also says more than 75 percent of its sales come from businesses with a number-one or number-two global market-share position. That positioning gives investors a framework for assessing the company’s portfolio strength, while pharmaceutical execution and medical-device demand remain important operating factors.
Investors can follow the real-time quote of Johnson & Johnson stock.
The S&P 500 provides the broader US market backdrop for investors.
More news and analyses are available on Johnson & Johnson stock.
